Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study

It has been hypothesized that low levels of C1 esterase inhibitor (C1-INH), a key inhibitor of the complement pathway, may play a role in the occurrence of adverse events (AEs) associated with intravenous immunoglobulin (IVIG) therapy. This open-label pilot study evaluated C1-INH replacement, with r...

Descripción completa

Detalles Bibliográficos
Autores principales: Melamed, Isaac R., Miranda, Holly, Heffron, Melinda, Harper, Joseph R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962274/
https://www.ncbi.nlm.nih.gov/pubmed/33737935
http://dx.doi.org/10.3389/fimmu.2021.632744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962274/
https://www.ncbi.nlm.nih.gov/pubmed/33737935
http://dx.doi.org/10.3389/fimmu.2021.632744

Ejemplares similares